Tuberculosis (TB) diagnosis typically involves a combination of screening tests, imaging, and laboratory confirmation. No single test can definitively diagnose TB on its own, so doctors layer multiple methods depending on whether they suspect latent infection (TB bacteria present but inactive) or active disease (symptoms and contagiousness). The process usually starts with a skin or blood test and, if those are positive, moves to chest X-rays and sputum samples.
Screening: Skin Test and Blood Test
The two front-line screening tools are the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs), which are blood tests. Neither one tells you whether TB is latent or active. They simply indicate whether your immune system has encountered TB bacteria at some point.
For the skin test, a small amount of purified protein from TB bacteria is injected just under the skin of your forearm. You return to a clinic 48 to 72 hours later so a healthcare worker can measure any raised, firm bump (not redness) at the injection site. What counts as “positive” depends on your risk level:
- 5 millimeters or more is positive for people with HIV, organ transplant recipients, anyone recently exposed to a person with active TB, or people on immune-suppressing medications.
- 10 millimeters or more is positive for people born in countries where TB is common, those living or working in shelters or correctional facilities, people with diabetes or severe kidney disease, children under 5, and people who inject drugs.
- 15 millimeters or more is positive for people with no known risk factors.
Blood tests work differently. A single blood draw is analyzed in a lab to measure how strongly your immune cells react to TB-specific proteins. Results are typically available within 24 to 48 hours and require only one visit. In countries with lower TB rates, both the skin test and blood tests have a specificity around 74 to 76 percent and a sensitivity around 63 to 65 percent for predicting who will go on to develop active TB. In other words, neither test is perfect, and both can miss some infections or flag people who won’t actually get sick.
BCG Vaccination and False Positives
If you received the BCG vaccine (common in many countries outside the United States), it can trigger a false-positive skin test. There is no reliable way to tell whether a positive skin test result came from the vaccine or from a real TB infection. Skin test reactivity from BCG is most likely in the first two years after vaccination in newborns, and it generally fades over time. However, repeated skin testing can actually boost the reaction in vaccinated people, making the problem worse. For this reason, blood tests are often preferred for people who have been vaccinated with BCG, since those tests use proteins not found in the vaccine strain and are less likely to give false positives.
Chest X-Rays and Imaging
When a screening test comes back positive, a chest X-ray is usually the next step. In adults without HIV, active pulmonary TB almost always produces an abnormal X-ray. Classic findings include infiltrates (cloudy patches in the lung tissue, often in the upper lobes) and cavities (hollow spaces where the bacteria have destroyed tissue). These patterns are suggestive but not unique to TB. Pneumonia, lung cancer, and fungal infections can look similar, so imaging alone does not confirm the diagnosis. It does, however, help determine how urgently lab confirmation is needed and whether the person might be infectious.
For people with HIV, chest X-rays can appear normal or show atypical patterns even when active TB is present, which makes laboratory testing even more critical in that population.
Sputum Samples and Lab Confirmation
The gold standard for diagnosing active pulmonary TB is finding the bacteria in a sample from your lungs. Most often, this means producing sputum (deep cough samples), usually collected on two or three separate occasions, often including an early-morning specimen.
The fastest initial look is a smear test, in which the sample is spread on a slide and stained to reveal acid-fast bacilli under a microscope. This can give results the same day, but it has limitations. The bacteria need to be present in fairly high numbers to be visible, so a negative smear does not rule out TB.
Culture is more sensitive. Your sputum is placed in a liquid growth medium and monitored for bacterial growth. Modern automated liquid culture systems detect TB bacteria faster than traditional methods, but results still take one to six weeks because the bacteria grow slowly. A positive culture is definitive proof of active TB and also provides live bacteria that can be tested against different drugs to identify which treatments will work.
Rapid Molecular Testing
Molecular tests have dramatically shortened the wait for reliable results. The most widely used is a cartridge-based system that simultaneously detects TB bacteria and resistance to rifampicin, one of the most important first-line drugs, in less than two hours. A sputum sample is loaded into the machine, and automated processing extracts and amplifies the bacteria’s DNA.
This technology is especially valuable in settings where quick decisions matter: emergency departments, HIV clinics, and resource-limited areas where patients may not return for follow-up. A positive molecular result can justify starting treatment immediately rather than waiting weeks for a culture. It also flags rifampicin resistance early, which changes the treatment plan significantly.
Drug Resistance Testing
Knowing that someone has TB is only half the equation. Doctors also need to know which drugs will actually kill the strain. Standard drug-resistant TB (sometimes called MDR-TB) does not respond to the two most effective first-line medications, so identifying resistance patterns is critical before or shortly after treatment begins.
Molecular methods can screen for specific genetic mutations linked to drug resistance. For rifampicin, the rapid cartridge test mentioned above covers this in the initial diagnostic step. For isoniazid, the other key first-line drug, laboratories look for mutations in particular genes that the bacteria need to activate the drug. Resistance to second-line injectable medications is detected by scanning different genetic regions. These molecular results can come back within days, compared to the weeks or months that traditional culture-based susceptibility testing requires.
Diagnosing TB Outside the Lungs
TB can infect almost any part of the body: lymph nodes, bones, the brain and spinal fluid, the lining around the lungs or heart, the abdomen, and the urinary tract. Diagnosing these extrapulmonary forms is harder because sputum tests are often negative and symptoms overlap with many other conditions.
The diagnostic approach depends on where the infection is suspected. Doctors collect specimens directly from the affected site. For swollen lymph nodes, that means a needle aspiration or biopsy. For suspected TB in the chest lining, a sample of pleural fluid is drawn. Spinal fluid, abdominal fluid, joint fluid, or urine may be collected for other sites. Typical findings in fluid samples that suggest TB include straw-colored fluid with high protein, a predominance of lymphocytes (a type of white blood cell), and positive results on rapid molecular testing or culture. Tissue biopsies can also be examined under a microscope for the characteristic clusters of immune cells, called granulomas, that form in response to TB bacteria.
Diagnosing TB in Children
Children, especially those under five, pose a unique diagnostic challenge. Young kids usually cannot cough up sputum on demand, and even when samples are obtained, the bacterial load in pediatric TB tends to be much lower than in adults. This makes smear tests and even cultures less reliable.
When sputum collection is not possible, clinicians often turn to gastric aspirates, samples of stomach fluid collected through a thin tube, typically first thing in the morning before the child has eaten. The idea is that children swallow mucus from their airways overnight, and TB bacteria can be recovered from the stomach contents. The yield from gastric aspirates is frequently low, however. In one study of 508 specimens from children 11 and under, only six were positive on microscopy and eight on culture. Because of these limitations, pediatric TB diagnosis relies more heavily on a combination of clinical signs (prolonged cough, poor weight gain, contact with an adult who has TB), screening test results, and chest imaging rather than waiting for microbiological proof.